Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells

Blood

Volumn 106, Issue 9, 2005, Pages 3223-3226

  Mayr, Christine ^b   Kofler, David M ^b   Büning, Hildegard ^b   Bund, Dagmar ^b   Hallek, Michael ^b   Wendtner, Clemens Martin ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; FIBROMODULIN; GAMMA INTERFERON; MURINE DOUBLE MINUTE 2 ANTIGEN; PROTEIN KW 13; PROTEIN P53; SURVIVIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; LEUKEMIA CELL; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE;

EID: 27644483147     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-04-1742     Document Type: Article

References (24)

1. Wierda G, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000;96:2917-2924.
2. Mayr C, Bund D, Schlee M, et al. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8 autologous T lymphocytes. Blood. 2005;105:1566-1573.
3. Schmidt SM, Schag K, Muller MR, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood. 2003;102:571-576.
4. Trojan A, Schultze JL, Witzens M, et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med. 2000;6:667-672.
5. Krackhardt AM, Witzens M, Harig S, et al. Identification of tumor associated antigens in chronic lymphocytic leukemia by SEREX. Blood. 2002;100:2123-2131.
6. Van den Hove LE, Van Gool SW, Vandenberghe P, et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia. 1997;11:572-580.
7. Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest. 1997;100:2757-2765.
8. Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 1998;101:1133-1141.
9. Cantwell M, Hua T, Pappas J, Kipps TJ. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med. 1997;3:984-989.
10. Wendtner CM, Kofler DM, Theiss HD, et al. Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood. 2002;100:1655-1661.
11. Cheson B, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
12. Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol. 2001;2:962-970.
13. 65-73 wild type peptide loaded on dendritic cells in vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand J Immunol. 2000;51:128-133.
14. Houbiers JGA, Nijman HW, von der Burg SH, et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol. 1993;23:2072-2077.
15. Würtzen PA, Claesson MH. A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope. Int J Cancer. 2002;99:568-572.
16. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A. 1995;92:11993-11997.
17. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 2001;61:869-872.
18. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001;61:5964-5968.
19. Garrone P, Neidhardt EM, Garcia E, Galibert L, von Kooten C, Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med. 1995;182:1265-1273.
20. Tan LC, Gudgeon N, Annels NE, et al. A re-evaluation of the frequency of CD8 T cells specific for EBV in healthy virus carriers. J Immunol. 1999;162:1827-1835.
21. Bendle GM, Holler A, Pang LK, et al. Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes. Cancer Res. 2004;64:8052-8056.
22. Soruri A, Fayyazi A, Gangl S, Griesinger C, Albrecht CA, Schlott T. In vitro generation of cytolytic T cells against human melanoma cells over-expressing HDM2. Anticancer Res. 2004;24:2141-2151.
23. Chikamatsu K, Albers A, Stanson J, et al. P53(110-124)-specific human CD4 T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8 T cells. Cancer Res. 2003;63:3675-3681.
24. Chu P, Deforce D, Pedersen IM, et al. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:3854-3859.